Overview

Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a single-dose, Randomized, two-period,cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult, human subjects.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Cetirizine
Levocetirizine
Criteria
Inclusion Criteria:

- Male and non-pregnant female human subjects, age in the range of 18 - 45 years (both
inclusive).

- Body weight within ± 15% of ideal weight as related to height and body frame according
to Life Insurance Corporation (LIC) Chart.

- Subjects with normal findings as determined by baseline history, physical examination
and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).

- Subjects with clinically acceptable findings as determined by haemogram, biochemistry,
serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray
(chest X-ray if required).

- Willingness to follow the protocol requirements as evidenced by written informed
consent.

- Confirming and agreeing to, not using any prescription and over the counter
medications including vitamins and minerals for 14 days prior to study and during the
course of the study.

- No history of drug abuse in the past one year.

- Non-smokers and non-alcoholics.

- For female subject is child bearing potential practicing acceptable method of birth
control for the duration of the study as judged by Investigator such as Condom, Foams,
Jellies,Diaphragm, Intrauterine device and Abstinence

- Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or
hysterectomy has been performed on the subject).

Exclusion Criteria:

- Known history of hypersensitivity to Levocetirizine or to Cetirizine, or related
drugs.

- Requiring medication for any ailment having enzyme-modifying activity in the previous
28 days, prior to dosing day.

- Any medical or surgical conditions, which might significantly interfere with the
functioning of gastrointestinal tract, blood-forming organs etc.

- History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric
diseases and bleeding tendency.

- Participation in a clinical drug study or bioequivalence study within 90 days prior to
present study.

- History of malignancy or other serious diseases.

- Refusal to abstain from food for at least ten (10.00) hours prior to receiving the
high-fat and high-calorie breakfast and for at least four (04.00) hours post-dose, in
each study period.

- Any contraindication to blood sampling or difficulty in accessibility of veins.

- Refusal to abstain from fluid for at least 01.00 hour prior to study drug
administration and for at least 01.00 additional hour post-dose, in each study period
except about 240 mL of water given during administration of study drug.

- Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea,
coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for
48.00 hours prior to dosing until the last blood sample collection of last study
period.

- Blood donation within 90 days prior to the commencement of the study.

- Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.

- Found positive in breath alcohol test done before check-in for each study period.

- Found positive in urine test for drugs of abuse done before check-in for each study
period.

- Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing
until the last blood sample collection of last study period.

- History of problem in swallowing Tablet(s).

- Female subject, demonstrating positive urine pregnancy test at the time of screening.

- Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic
Gonadotropin) test before check-in for each study period.

- Female subject, currently breast feeding or lactating.

- Female subjects not willing to use acceptable method of contraception from the date of
screening until the completion of the study.